Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

41 through 50 of 232

Relevance: Medium-High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Guideline : FDA issues alert on a drug combination to treat triple-negative breast cancer

Most relevant for: People with metastatic triple-negative breast cancer

The immunotherapy drug Tecentriq (atezolizumab) is approved for use with Abraxane (nab-paclitaxel) to treat metastatic triple-negative breast cancer. Tecentriq is NOT approved for use with Taxol (paclitaxel). The Food and Drug Administration has issued an alert to doctors, researchers and patients warning that Tecentriq should not be used in combination with Taxol to treat patients with advanced triple-negative breast cancer. (09/18/20)

Read More
FDA issues alert on a drug combination to treat triple-negative breast cancer

Relevance: Medium-Low

pointerRelevance

Strength of Science: Medium-Low

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Dairy milk may slightly raise breast cancer risk

Most relevant for: Women who consume dairy or soy

Debate continues about whether consuming soy or dairy products increases breast cancer risk. This study looked at a large number of women and found no link between soy and breast cancer risk. The study did find that postmenopausal women who drank dairy milk have a small increase in breast cancer risk. (09/04/20)

Read More
Dairy milk may slightly raise breast cancer risk

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Quality of Writing: High

pointerQuality of Writing
View Related Clinical Trials

Study : Among women with breast cancer, who should have genetic testing for an inherited mutation?

Most relevant for: Women diagnosed with breast cancer who do not know if they have an inherited mutation in a gene linked to breast cancer

Which breast cancer patients should consider genetic testing? Knowing whether you have an inherited mutation may inform the decisions you and your healthcare provider make about treatment. But it can also increase stress and anxiety. This XRAY reviews a study of how different guidelines affect genetic testing recommendations for people with breast cancer. (8/27/20)

Read More
Among women with breast cancer, who should have genetic testing for an inherited mutation?

Relevance: Medium-High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : New PARP inhibitor veliparib showed benefit as first-line treatment for ovarian cancer

Most relevant for: Women with advanced-stage ovarian cancer

Treatment with veliparib may benefit women with advanced ovarian cancer. A recent clinical trial shows that this new PARP inhibitor may delay progression of cancer when combined with chemotherapy and when continued alone as a maintenance therapy. (8/18/20)

Read More
New PARP inhibitor veliparib showed benefit as first-line treatment for ovarian cancer

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Insulin resistance linked to differences in breast cancer survival between Black and White women

Most relevant for: Black women

Black women are more likely to die from breast cancer compared to White women. More Black women have a condition called insulin resistance than White women.  This study found that insulin resistance might be one of the reasons that Black women are more likely than White women to die from breast cancer. Additional research is needed to see if lowering insulin levels will improve breast cancer survival in Black women. (07/30/20)

Read More
Insulin resistance linked to differences in breast cancer survival between Black and White women

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Healthy romantic relationships may decrease stress and inflammation for breast cancer survivors

Most relevant for: Women with breast cancer who have romantic partners

Satisfying romantic relationships may improve outcomes for women with breast cancer. In a new study, women who were more satisfied with their romantic relationships experienced less stress and lower inflammation. This study suggests that decreasing stress may be beneficial for breast cancer survivors. (7/25/20)

Read More
Healthy romantic relationships may decrease stress and inflammation for breast cancer survivors

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science
View Related Clinical Trials

Update : FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer

Most relevant for: Women with advanced ovarian cancer whose tumor has a BRCA mutation or a type of tumor marker called homologous recombination deficiency (HRD)

The FDA has approved the first drug combination to be used as a first-line maintenance therapy for some women with advanced ovarian cancer. (7/7/2020)

Read More
FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2

Most relevant for: People with metastatic breast cancer with an inherited mutation or tumor with a BRCA mutation

Early results of a small study showed that women with metastatic breast cancer and an inherited  mutation in PALB2 or an acquired tumor mutation in BRCA1 or BRCA2 benefitted from the PARP inhibitor olaparib (Lynparza). (6/18/20)

Read More
Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2

Relevance: High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Study : What is the risk for contralateral breast cancer in women with an inherited BRCA1, BRCA2 or TP53 mutation?

Most relevant for: Women diagnosed with breast cancer before age 40

For women who have been diagnosed with breast cancer, knowing their risk of breast cancer in the other (contralateral) breast can help them make decisions about surgery and surveillance. Research has shown that women with an inherited mutation in BRCA1 or BRCA2 have an increased risk for contralateral breast cancer. A British study shows that women with an inherited mutation in the TP53 gene may have an increased risk for contralateral breast cancer, which is even higher greater than the risk of women with a BRCA1 or BRCA2 mutation. (6/6/20)

Read More
What is the risk for contralateral breast cancer in women with an inherited BRCA1, BRCA2 or TP53 mutation?

Relevance: High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Update : PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer

Most relevant for: Men with metastatic castration-resistant prostate cancer who have certain inherited or tumor mutations in DNA repair genes

The FDA approved two PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) for treatment of metastatic castration-resistant prostate cancer (mCRPC) in men who have certain inherited mutations or tumor mutations. (6/1/20)

Read More
PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer